A facile adenosine triphosphate‑responsive nanoplatform for efficacious therapy of esophageal cancer

Wang, Jinglong; Xu, Linhao; Liu, Xiaotong; Yang, Ronghua; Wang, Dong

doi:10.3892/ol.2020.11969

Cited by 7 publications

(4 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tumor microenvironment-responsive NDDS can serve as intelligent nanoplatforms for controlled drug release by endogenous or exogenous stimuli. Endogenous factors contain differences in tumor microenvironments from healthy tissue, including pH, enzymes, glutathione, reactive oxygen hypoxia, 96 adenosine-triphosphate, 97 and inflammatory factors. 98 PROTACs can be conjugated onto the surface of nanoplatforms with tumor microenvironment-cleavable linkers.…”

Section: Discussionmentioning

confidence: 99%

Nano-Proteolysis Targeting Chimeras (Nano-PROTACs) in Cancer Therapy

Song,

Dong,

et al. 2024

IJN

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Nano-Proteolysis Targeting Chimeras (Nano-PROTACs) in Cancer Therapy

Song,

Dong,

et al. 2024

IJN

View full text Add to dashboard Cite

“…Measure the size distribution and zeta-potential of BUD-LNPs using DLS at 0 h, 2 h, 4 h, 6 h, 8 h, 12 h, 24 h, 36 h, 48 h, and 72 h, respectively. 20…”

Section: Stability Of Bud-lnpsmentioning

confidence: 99%

Preparation of Budesonide-Loaded Liposomal Nanoparticles for Pulmonary Delivery and Their Therapeutic Effect in OVA-Induced Asthma in Mice

Zuo,

Gu,

Guo

et al. 2024

IJN

View full text Add to dashboard Cite

Inhaled corticosteroids, including budesonide (BUD), are widely employed for the treatment of asthma. However, the frequent use of corticosteroids is associated with numerous adverse effects and poses challenges to ongoing drug therapy and patient adherence. Budesonide liposomal nanoparticles (BUD-LNPs) were developed to improve the bioavailability of the drug and thereby improve the effectiveness of asthma treatment. Methods: BUD-LNPs were prepared via thin-film hydration, and the characterizations, stability, and in vitro release of BUD-LNPs were studied. In vitro cellular uptake was observed by laser-scanning confocal microscope (LSCM) and flow cytometry. And the in vitro anti-inflammatory activity of BUD-LNPs was evaluated by measuring the expression of pro-inflammatory cytokines in activated macrophages. Besides, the accumulation time in the lung of drugs delivered via liposomal carriers and free drugs was compared in vivo. And the in vivo therapeutic efficacy of BUD-LNPs was assessed in OVA-induced asthmatic mice. Finally, in vivo biosafety assessment was performed. Results: The particle size, PDI, and zeta potential of BUD-LNPs were 127.63±1.33 nm, 0.27±0.02, and 3.33±0.13 mV, respectively. BUD-LNPs exhibited excellent biosafety and anti-inflammatory activity in vitro. Furthermore, compared with the free drugs, the utilization of liposomal nano-vehicles for drugs delivery could effectively extend the duration of drugs accumulation in the pulmonary system. Additionally, treatment with BUD-LNPs alleviated airway hyperresponsiveness, reduced airway mucus secretion, and mitigated pulmonary inflammation in OVA-induced asthmatic mice. And the BUD-LNPs demonstrated superior therapeutic efficacy compared to free BUD. Conclusion: BUD-LNPs was successfully prepared with excellent stability and sustained release for 24 h in vitro. The data of antiinflammatory activity, asthma therapeutic effects and safety studies indicated that drug delivery mediated by liposomal nano-vehicles was a feasible and desirable strategy for medical strategy and showed great promise in the clinical therapy of asthma.

show abstract

“…The chemotherapeutic drug doxorubicin was inserted into an ATP aptamer (Ap) to form a double-stranded DNA (“DNA duplex”) which was subsequently condensed using polyethyleneimine (PEI) to construct the final nanoplatform (PEI-Ap-DNA-DOX). After internalization by cancer cells, the doxorubicin-loaded DNA duplex can be opened and released within the intracellular environment rich in ATP ( Wang et al, 2020c ). Similarly, Huang et al developed a novel formulation of docetaxel, called trimethyl chitosan-DTX (TMC-DTX) applying to the treatment of esophageal cancer, and investigated its effects.…”

Section: The Applications Of Nanocarriers In Therapeutic and Diagnosi...mentioning

confidence: 99%

Nanodrugs systems for therapy and diagnosis of esophageal cancer

Zhang

Yue

et al. 2023

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

With the increasing incidence of esophageal cancer, its diagnosis and treatment have become one of the key issues in medical research today. However, the current diagnostic and treatment methods face many unresolved issues, such as low accuracy of early diagnosis, painful treatment process for patients, and high recurrence rate after recovery. Therefore, new methods for the diagnosis and treatment of esophageal cancer need to be further explored, and the rapid development of nanomaterials has brought new ideas for solving this problem. Nanomaterials used as drugs or drug delivery systems possess several advantages, such as high drug capacity, adjustably specific targeting capability, and stable structure, which endow nanomaterials great application potential in cancer therapy. However, even though the nanomaterials have been widely used in cancer therapy, there are still few reviews on their application in esophageal cancer, and systematical overview and analysis are deficient. Herein, we overviewed the application of nanodrug systems in therapy and diagnosis of esophageal cancer and summarized some representative case of their application in diagnosis, chemotherapy, targeted drug, radiotherapy, immunity, surgery and new therapeutic method of esophageal cancer. In addition, the nanomaterials used for therapy of esophageal cancer complications, esophageal stenosis or obstruction and oesophagitis, are also listed here. Finally, the challenge and the future of nanomaterials used in cancer therapy were discussed.

show abstract

A facile adenosine triphosphate‑responsive nanoplatform for efficacious therapy of esophageal cancer

Cited by 7 publications

References 25 publications

Nano-Proteolysis Targeting Chimeras (Nano-PROTACs) in Cancer Therapy

Nano-Proteolysis Targeting Chimeras (Nano-PROTACs) in Cancer Therapy

Preparation of Budesonide-Loaded Liposomal Nanoparticles for Pulmonary Delivery and Their Therapeutic Effect in OVA-Induced Asthma in Mice

Nanodrugs systems for therapy and diagnosis of esophageal cancer

Contact Info

Product

Resources

About